March 3, 2015 Pulmokine announced today that it has entered into an agreement with Broadview Ventures for $1 Million. Proceeds will be used to advance Pulmokine’s lead candidate, PK10571, into Phase 1 clinical trials in patients with pulmonary arterial hypertension (PAH).

Press Release